Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRTG

Portage Biotech (PRTG) Stock Price, News & Analysis

Portage Biotech logo

About Portage Biotech Stock (NASDAQ:PRTG)

Key Stats

Today's Range
$6.80
$9.43
50-Day Range
$6.81
$9.97
52-Week Range
$5.23
$12.24
Volume
377,941 shs
Average Volume
194,833 shs
Market Capitalization
$8.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Portage Biotech Inc. (NASDAQ: PRTG) is a clinical‐stage biotechnology company focused on building a diversified portfolio of innovative therapeutics targeting rare diseases and oncology indications. Leveraging an asset‐centric business model, Portage Biotech acquires and in‐licenses development‐stage compounds from academic institutions and biotechnology partners, then advances these assets through preclinical studies and early‐stage clinical trials within dedicated subsidiary entities.

The company’s pipeline spans small molecules, biologics and cell therapies, with programs directed at conditions such as myeloproliferative disorders, inherited blood disorders and solid tumor oncology. By organizing each development program under a stand‐alone subsidiary, Portage Biotech centralizes shared functions—such as regulatory affairs, manufacturing and clinical operations—while allowing focused teams to drive individual assets toward key value‐creating milestones.

Headquartered in New York, Portage Biotech maintains collaborations with research institutions in North America and Europe to expand its discovery footprint and accelerate candidate selection. The company’s management team brings experience from established biopharmaceutical and venture‐backed organizations, supporting a strategy of disciplined capital allocation and milestone‐driven advancement.

Portage Biotech’s approach aims to unlock value in early‐stage projects through targeted partnerships and efficient resource deployment, positioning the company to out‐license or co‐develop programs as they progress toward pivotal clinical readouts.

AI Generated. May Contain Errors.

Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRTG Stock News Headlines

Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
PRTG Portage Biotech Inc. - Seeking Alpha
See More Headlines

PRTG Stock Analysis - Frequently Asked Questions

Portage Biotech Inc. (NASDAQ:PRTG) issued its quarterly earnings data on Tuesday, November, 26th. The company reported ($1.26) EPS for the quarter.

Portage Biotech's stock reverse split on Thursday, August 15th 2024.The 1-20 reverse split was announced on Tuesday, August 13th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Portage Biotech investors own include Meta Platforms (META), Alimera Sciences (ALIM), AirMedia Group (ANTE), Broadcom (AVGO), Barnwell Industries (BRN) and Crescent Biopharma (CBIO).

Company Calendar

Last Earnings
11/26/2024
Today
8/17/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PRTG
CIK
1095435
Fax
N/A
Employees
6
Year Founded
1973

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.02
Quick Ratio
2.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.79) per share
Price / Book
-9.66

Miscellaneous

Outstanding Shares
1,050,000
Free Float
608,000
Market Cap
$8.01 million
Optionable
Optionable
Beta
0.25
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:PRTG) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners